TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00797706` - Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers	Phase 1/Phase 2
Active, not recruiting	`NCT02130310` - Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers	Phase 3
Recruiting	`NCT00678847` - Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy	Phase 2/Phase 3
Recruiting	`NCT03576989` - Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults	N/A

See also

Status

Clinical Trial

Phase

Active, not recruiting

NCT00797706 - Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers

Phase 1/Phase 2

Active, not recruiting

NCT02130310 - Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers

Phase 3

Recruiting

NCT00678847 - Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy

Phase 2/Phase 3

Recruiting

NCT03576989 - Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT02936128
Study type	Interventional
Source	Osiris Therapeutics
Contact
Status	Terminated
Phase	Phase 4
Start date	July 2016
Completion date	April 2017

TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms